Chief Operating Officer
As founder and CEO of ZIRUS, David oversaw the development of a host based antiviral drug platforms. David was the Head of the Biotechnology Patent Group at Needle & Rosenberg as the group rose to national prominence through its association with the NIH, NIAID, and the CDC. He was also a co-founder of Georgia Venture Partners and a co-founder and member of the Board of Directors at Maxia Pharmaceuticals, where he directed the strategy of the drug patent portfolio before it was acquired by Incyte Pharmaceuticals.
